左乙拉西坦与其他抗癫痫药物急性肾衰竭发生率比较:一项自愿性上市后安全性研究
本研究利用美国IBM MarketScan数据库(2008年1月至2017年12月),对新使用抗癫痫药物且无既往肾功能不全的患者随访30天,比较左乙拉西坦与其他抗癫痫药物相关急性肾衰竭的发生率。单药队列110,336例,多药队列96,215例;总体粗发生率分别为每10,000例患者6.0和6.5例。调整后单药队列IRR为1.37(95%CI 0.80-2.34),多药队列IRR为0.94(95%CI 0.51-1.74),差异均小且置信区间兼容微小保护或危害效应。
要点
- 抗癫痫药物新使用者急性肾衰竭发生率很低。
- 左乙拉西坦单药治疗者急性肾衰竭风险与其他抗癫痫药物差异小。
- 多药治疗者左乙拉西坦与其他抗癫痫药物风险差异兼容无效值。
核心结论
- 抗癫痫药物新使用者中急性肾衰竭发生率很低。
- 无既往抗癫痫药物暴露者,起始左乙拉西坦与其他抗癫痫药物相关的急性肾衰竭风险差异小,95%CI兼容微小保护或危害效应。
- 接受多药治疗者,左乙拉西坦与其他抗癫痫药物的风险差异兼容无效值,95%CI兼容微小保护或危害效应。
研究设计与样本
- 自愿性上市后安全性研究,使用IBM MarketScan数据库(美国,2008年1月至2017年12月)。
- 纳入无既往肾功能不全的新使用抗癫痫药物患者,随访30天。
- 急性肾衰竭定义为住院或急诊索赔中的诊断。
- 单药队列110,336例患者,多药队列96,215例患者。
- 估计调整后发生率、发生率比(IRR)和发生率差(IRD)。
主要发现
- 单药队列总体粗急性肾衰竭发生率为每10,000例患者6.0例(起始后30天内)。
- 多药队列总体粗急性肾衰竭发生率为每10,000例患者6.5例(起始后30天内)。
- 单药队列调整后IRR为1.37(95%CI 0.80-2.34),IRD为每10,000患者月2.0例(95%CI -1.12至5.12)。
- 多药队列调整后IRR为0.94(95%CI 0.51-1.74),IRD为每10,000患者月-0.42例(95%CI -4.01至3.17)。
临床怎么用
- 临床可参考本研究中急性肾衰竭发生率很低的结果,但需结合患者个体情况评估肾功能。
- 对于无既往肾功能不全的新使用抗癫痫药物患者,左乙拉西坦与其他抗癫痫药物在急性肾衰竭风险上的差异小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute kidney injury is an expected adverse drug reaction listed in the European Union (EU) Summary of Product Characteristics (SmPC) for levetiracetam, one of the most widely used modern antiseizure medications (ASMs). OBJECTIVE: We conducted a voluntary post-authorization safety study to characterize the rate of acute renal failure (ARF) in patients exposed to levetiracetam versus other ASMs. METHODS: New users of ASMs without prior renal dysfunction were identified and followed for 30 days in the IBM® MarketScan® database (USA, January 2008-December 2017). ARF was defined as a diagnosis on inpatient or emergency department claims. We estimated adjusted incidence rates, incidence rate ratios (IRRs), and incidence rate differences (IRDs) of ARF in patients initiating levetiracetam versus other ASMs. RESULTS: Overall, 110,336 patients were eligible for the monotherapy cohort and 96,215 were eligible for the polytherapy cohort. The overall crude rate of ARF following a new ASM was 6.0 and 6.5 per 10,000 patients for the 'monotherapy' and 'polytherapy' cohorts, respectively, in the first 30 days after the index date. In the monotherapy cohort, the IRR for ARF was 1.37 (95% confidence interval [CI] 0.80-2.34) and the corresponding IRD was 2.0 (95% CI - 1.12 to 5.12) additional ARFs per 10,000 patient-months. In the polytherapy cohort, the adjusted IRR for ARF was 0.94 (95% CI 0.51-1.74) and the corresponding IRD was - 0.42 cases per 10,000 patient-months (95% CI - 4.01 to 3.17). CONCLUSIONS: The rate of ARFs in ASM new users was very low. In patients without prior ASMs, the estimated difference in risk of ARF associated with initiation of levetiracetam versus initiation of other ASMs was small, with 95% CIs compatible with small protective or harmful effects. In patients receiving polytherapy, the difference was compatible with the null and the 95% CI with small protective or harmful effects.
引用
- Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, et al. Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety Study. Drug Saf. 2022. PMID: 35761158. doi:10.1007/s40264-022-01193-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。